Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment

Cancer Microenvironment

Volumn 5, Issue 1, 2012, Pages 83-93

  Hugo, Honor J ^a   Lebret, Stephanie ^b   Tomaskovic Crook, Eva ^a   Ahmed, Nuzhat ^c,d   Blick, Tony ^a   Newgreen, Donald F ^e   Thompson, Erik W ^a,d   Ackland, M Leigh ^b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Breast cancer; EMT; IL 6; Inflammation; Mast cells; Stroma

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL INVASION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; INVASIVE NONINFLAMMATORY BREAST CANCER; LASER CAPTURE MICRODISSECTION; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84860619381     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-012-0098-7     Document Type: Article

References (56)

1. JM Lopez-Novoa MA Nieto 2009 Inflammation and EMT: an alliance towards organ fibrosis and cancer progression EMBO Mol Med 1 303 314 10.1002/emmm.200900043 20049734 10.1002/emmm.200900043 1:CAS:528: DC%2BD1MXhsVSltL%2FJ
2. A Mantovani P Allavena A Sica F Balkwill 2008 Cancer-related inflammation Nature 454 436 444 10.1038/nature07205 18650914 10.1038/nature07205 1:CAS:528:DC%2BD1cXovV2mtbg%3D
3. HL Chua P Bhat-Nakshatri SE Clare A Morimiya S Badve H Nakshatri 2007 NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 Oncogene 26 711 724 10.1038/sj.onc.1209808 16862183 10.1038/sj.onc.1209808 1:CAS:528:DC%2BD2sXhtFGmurs%3D (Pubitemid 46204250)
4. S Julien I Puig E Caretti J Bonaventure L Nelles F van Roy, et al. 2007 Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition Oncogene 26 7445 7456 10.1038/sj.onc.1210546 17563753 10.1038/sj.onc.1210546 1:CAS:528:DC%2BD2sXhtlCrsLfK (Pubitemid 350158710)
5. JC Tse R Kalluri 2007 Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment J Cell Biochem 101 816 829 10.1002/jcb.21215 17243120 10.1002/jcb.21215 1:CAS:528:DC%2BD2sXnvVSqu70%3D (Pubitemid 47040864)
6. K Dvorakova CM Payne L Ramsey H Holubec R Sampliner J Dominguez, et al. 2004 Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus Clin Cancer Res 10 2020 2028 15041721 10.1158/1078-0432.CCR- 0437-03 1:CAS:528:DC%2BD2cXisVGlu7Y%3D (Pubitemid 38375562)
7. A Ekbom C Helmick M Zack HO Adami 1990 Increased risk of large-bowel cancer in Crohn's disease with colonic involvement Lancet 336 357 359 1975343 10.1016/0140-6736(90)91889-I 1:STN:280:DyaK3czmt12rtQ%3D%3D (Pubitemid 20264156)
8. H Kai Y Kitadai M Kodama S Cho T Kuroda M Ito, et al. 2005 Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma Anticancer Res 25 709 713 15868900 1:CAS:528:DC%2BD2MXkt1Ggs74%3D (Pubitemid 40546835)
9. EJ Park JH Lee GY Yu G He SR Ali RG Holzer, et al. 2010 Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 140 197 208 10.1016/j.cell.2009.12.052 20141834 10.1016/j.cell.2009.12.052 1:CAS:528:DC%2BC3cXkvVWitLw%3D
10. HF Dvorak 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1650 1659 10.1056/NEJM198612253152606 3537791 10.1056/NEJM198612253152606 1:STN:280:DyaL2s%2FmsV2mtw%3D%3D (Pubitemid 17052899)
11. M Hibi K Nakajima T Hirano 1996 IL-6 cytokine family and signal transduction: a model of the cytokine system J Mol Med 74 1 12 8834766 10.1007/BF00202068 1:CAS:528:DyaK28XhtlOmtrk%3D (Pubitemid 26035753)
12. JA Jazayeri GJ Carroll AB Vernallis 2010 Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists Int Immunopharmacol 10 1 8 10.1016/j.intimp. 2009.09.019 19804846 10.1016/j.intimp.2009.09.019 1:CAS:528:DC%2BC3cXjsl2jug%3D%3D
13. BB Aggarwal P Gehlot 2009 Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9 351 369 10.1016/j.coph.2009.06.020 19665429 10.1016/j.coph.2009.06.020 1:CAS:528:DC%2BD1MXhtVenurnI
14. WA Goodman AD Levine JV Massari H Sugiyama TS McCormick KD Cooper 2009 IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells J Immunol 183 3170 3176 10.4049/jimmunol.0803721 19648274 10.4049/jimmunol.0803721 1:CAS:528:DC%2BD1MXhtVWrs73F
15. SC Lebret DF Newgreen EW Thompson ML Ackland 2007 Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors Breast Cancer Res 9 R19 10.1186/bcr1656 17311675 10.1186/bcr1656 (Pubitemid 350215142)
16. SC Lebret DF Newgreen MC Waltham JT Price EW Thompson ML Ackland 2006 Myoepithelial molecular markers in human breast carcinoma PMC42-LA cells are induced by extracellular matrix and stromal cells In Vitro Cell Dev Biol Anim 42 298 307 10.1290/0601004.1 17316063 1:CAS:528:DC%2BD2sXhvFyrsrg%3D (Pubitemid 46224684)
17. EW Thompson S Paik N Brunner CL Sommers G Zugmaier R Clarke, et al. 1992 Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines J Cell Physiol 150 534 544 10.1002/jcp. 1041500314 1537883 10.1002/jcp.1041500314 1:CAS:528:DyaK38XhslWhur4%3D
18. SS McAllister RA Weinberg 2010 Tumor-host interactions: a far-reaching relationship J Clin Oncol 28 4022 4028 10.1200/JCO.2010.28.4257 20644094 10.1200/JCO.2010.28.4257
19. L Kozlowski I Zakrzewska P Tokajuk MZ Wojtukiewicz 2003 Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients Rocz Akad Med Bialymst 48 82 84 14737948 1:CAS:528:DC%2BD2cXitFCntA%3D%3D
20. R Salgado S Junius I Benoy P Van Dam P Vermeulen E Van Marck, et al. 2003 Circulating interleukin-6 predicts survival in patients with metastatic breast cancer Int J Cancer 103 642 646 10.1002/ijc.10833 12494472 10.1002/ijc.10833 1:CAS:528:DC%2BD3sXmtFKnsw%3D%3D (Pubitemid 36091468)
21. GJ Zhang I Adachi 1999 Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma Anticancer Res 19 1427 1432 10365118 1:STN:280:DyaK1M3ptlCmsA%3D%3D (Pubitemid 29257471)
22. KS Asgeirsson K Olafsdottir JG Jonasson HM Ogmundsdottir 1998 The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer Cytokine 10 720 728 10.1006/cyto.1998.0349 9770334 10.1006/cyto.1998.0349 1:CAS:528:DyaK1cXmslKitLw%3D (Pubitemid 28457117)
23. MZ Hussein A Al Fikky I Abdel Bar O Attia 2004 Serum IL-6 and IL-12 levels in breast cancer patients Egypt J Immunol 11 165 170 16734129
24. K Arihiro H Oda M Kaneko K Inai 2000 Cytokines facilitate chemotactic motility of breast carcinoma cells Breast Cancer 7 221 230 11029802 10.1007/BF02967464 1:STN:280:DC%2BD3M3mvFKruw%3D%3D
25. NJ Sullivan AK Sasser AE Axel F Vesuna V Raman N Ramirez, et al. 2009 Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells Oncogene 28 2940 2947 10.1038/onc.2009.180 19581928 10.1038/onc.2009.180 1:CAS:528:DC%2BD1MXotF2qsLo%3D
26. HJ Hugo MI Kokkinos T Blick ML Ackland EW Thompson DF Newgreen 2010 Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study Cells Tissues Organs 193 23 40 10.1159/000320174 21051859 10.1159/000320174
27. H Hugo ML Ackland T Blick MG Lawrence JA Clements ED Williams, et al. 2007 Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression J Cell Physiol 213 374 383 10.1002/jcp. 21223 17680632 10.1002/jcp.21223 1:CAS:528:DC%2BD2sXhtFKnu7rE (Pubitemid 47509716)
28. R Groppo JD Richter 2011 CPEB control of NF-kappaB nuclear localization and interleukin-6 production mediates cellular senescence Mol Cell Biol 31 2707 2714 10.1128/MCB.05133-11 21536657 10.1128/MCB.05133-11 1:CAS:528: DC%2BC3MXosFKjsL4%3D
29. Neveu WA, Bernardo E, Allard JL, Nagaleekar V, Wargo MJ, Davis RJ et al (2011) Fungal Allergen {beta}-glucans Trigger p38 MAPK-mediated IL-6 Translation in Lung Epithelial Cells. Am J Respir Cell Mol Biol. doi: 10.1165/rcmb.2011- 0054OC
30. B Van Camp I Van Riet 1998 Homing mechanisms in the biology of multiple myeloma Verh K Acad Geneeskd Belg 60 163 194 9803879
31. D Ribatti E Crivellato 2009 The controversial role of mast cells in tumor growth Int Rev Cell Mol Biol 275 89 131 10.1016/S1937-6448(09)75004-X 19491054 10.1016/S1937-6448(09)75004-X 1:CAS:528:DC%2BD1MXhtVSnsbbE
32. RM Amini K Aaltonen H Nevanlinna R Carvalho L Salonen P Heikkila, et al. 2007 Mast cells and eosinophils in invasive breast carcinoma BMC Cancer 7 165 10.1186/1471-2407-7-165 17727696 10.1186/1471-2407-7-165 (Pubitemid 350054212)
33. S Dabiri D Huntsman N Makretsov M Cheang B Gilks C Bajdik, et al. 2004 The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis Mod Pathol 17 690 695 10.1038/modpathol. 3800094 15044916 10.1038/modpathol.3800094 (Pubitemid 38715492)
34. M Samoszuk E Kanakubo JK Chan 2005 Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts BMC Cancer 5 121 10.1186/1471-2407-5-121 16176582 10.1186/1471-2407-5-121 (Pubitemid 41461014)
35. S Maltby K Khazaie KM McNagny 2009 Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation Biochim Biophys Acta 1796 19 26 10.1016/j.bbcan.2009.02.001 19233249 1:CAS:528:DC%2BD1MXhtVenurvO
36. PR Burd HW Rogers JR Gordon CA Martin S Jayaraman SD Wilson, et al. 1989 Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines J Exp Med 170 245 257 2473161 10.1084/jem.170.1.245 1:CAS:528:DyaL1MXkvFGhsb4%3D (Pubitemid 19179708)
37. L Hultner H Szots M Welle J Van Snick J Moeller P Dormer 1989 Mouse bone marrow-derived IL-3-dependent mast cells and autonomous sublines produce IL-6 Immunology 67 408 413 2788129 1:STN:280:DyaL1MzjvFGktQ%3D%3D (Pubitemid 19178862)
38. E Gyotoku E Morita Y Kameyoshi T Hiragun S Yamamoto M Hide 2001 The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice Arch Dermatol Res 293 508 514 11820727 10.1007/PL00007465 1:CAS:528:DC%2BD38XhtFWqsL0%3D
39. SM Fitzgerald SA Lee HK Hall DS Chi G Krishnaswamy 2004 Human lung fibroblasts express interleukin-6 in response to signaling after mast cell contact Am J Respir Cell Mol Biol 30 585 593 10.1165/rcmb.2003-0282OC 14565941 10.1165/rcmb.2003-0282OC 1:CAS:528:DC%2BD2cXjt1yjsL8%3D (Pubitemid 38457192)
40. ZQ Hu WH Zhao T Shimamura 2007 Regulation of mast cell development by inflammatory factors Curr Med Chem 14 3044 3050 18220740 10.2174/ 092986707782793998 1:CAS:528:DC%2BD1cXhtlSrsL4%3D (Pubitemid 350226973)
41. MK Dabbous SM North L Haney DA Tipton GL Nicolson 1995 Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts Clin Exp Metastasis 13 33 41 7820954 10.1007/BF00144016 1:STN:280:DyaK2M7itV2htw%3D%3D
42. S Ch'ng RA Wallis L Yuan PF Davis ST Tan 2006 Mast cells and cutaneous malignancies Mod Pathol 19 149 159 10.1038/modpathol.3800474 16258517 10.1038/modpathol.3800474 (Pubitemid 43250990)
43. IT Harvima G Nilsson A Naukkarinen 2010 Role of mast cells and sensory nerves in skin inflammation G Ital Dermatol Venereol 145 195 204 20467393 1:STN:280:DC%2BC3czjsVOgug%3D%3D
44. BJ Boersma M Reimers M Yi JA Ludwig BT Luke RM Stephens, et al. 2008 A stromal gene signature associated with inflammatory breast cancer Int J Cancer 122 1324 1332 10.1002/ijc.23237 17999412 10.1002/ijc.23237 1:CAS:528: DC%2BD1cXit1yhsLk%3D (Pubitemid 351287233)
45. T Blick E Widodo H Hugo M Waltham ME Lenburg RM Neve, et al. 2008 Epithelial mesenchymal transition traits in human breast cancer cell lines Clin Exp Metastasis 25 629 642 10.1007/s10585-008-9170-6 18461285 10.1007/s10585-008-9170-6 1:STN:280:DC%2BD1cvltFelsA%3D%3D
46. L D'Anello P Sansone G Storci V Mitrugno G D'Uva P Chieco, et al. 2010 Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells Mol Cancer 9 300 10.1186/1476-4598-9-300 21092249 10.1186/1476-4598-9-300
47. SP Gao KG Mark K Leslie W Pao N Motoi WL Gerald, et al. 2007 Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas J Clin Invest 117 3846 3856 10.1172/JCI31871 18060032 10.1172/JCI31871 1:CAS:528:DC%2BD2sXhsValsL%2FO (Pubitemid 350224094)
48. DD Schlaepfer S Hou ST Lim A Tomar H Yu Y Lim, et al. 2007 Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression J Biol Chem 282 17450 17459 10.1074/jbc.M610672200 17438336 10.1074/jbc.M610672200 1:CAS:528:DC%2BD2sXmt1ektrk%3D (Pubitemid 47100318)
49. ST Edwards AC Cruz S Donnelly PF Dazin ES Schulman KD Jones, et al. 2005 c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in interstitial lung diseases J Pathol 206 279 290 10.1002/path.1780 15887294 10.1002/path.1780 1:CAS:528:DC%2BD2MXmvVartLs%3D (Pubitemid 40903192)
50. Y Hirabayashi T Ishii H Harigae 2010 Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice Rheumatol Int 30 1041 1048 10.1007/s00296-009-1095-0 19701637 10.1007/s00296-009-1095-0 1:CAS:528:DC%2BC3cXmsFOqs7o%3D
51. JA Singh S Beg MA Lopez-Olivo 2010 Tocilizumab for rheumatoid arthritis Cochrane Database Syst Rev 7 CD008331 10.1002/14651858.CD008331.pub2 20614469
52. Brietzke E, Scheinberg M, Lafer B (2010) Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Med Hypotheses. doi: 10.1016/j.mehy.2010.08.021
53. N Nishimoto 2010 Interleukin-6 as a therapeutic target in candidate inflammatory diseases Clin Pharmacol Ther 87 483 487 10.1038/clpt.2009.313 20182422 10.1038/clpt.2009.313 1:STN:280:DC%2BC3c7pslOqtQ%3D%3D
54. M Fulciniti T Hideshima C Vermot-Desroches S Pozzi P Nanjappa Z Shen, et al. 2009 A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma Clin Cancer Res 15 7144 7152 10.1158/1078-0432.CCR-09-1483 19934301 10.1158/1078-0432.CCR-09-1483 1:CAS:528:DC%2BD1MXhsFSnu7zM
55. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S et al (2011) The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. doi: 10.1002/pros.21362
56. JF Rossi S Negrier ND James I Kocak R Hawkins H Davis, et al. 2011 A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer Br J Cancer 103 1154 1162 10.1038/sj.bjc.6605872 10.1038/sj.bjc.6605872